Navigation Links
Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
Date:4/5/2011

MINNEAPOLIS, April 5, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that two private insurance payers have elected to cover  posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder (OAB) and associated symptoms. Effective April 1, 2011, UnitedHealthcare, a nationwide private insurer, and, effective March 17, 2011, Excellus BlueCross BlueShield (BCBS), a regional insurer in upstate New York, initiated coverage of PTNS.  

UnitedHealthcare is the largest single health insurer in the United States covering approximately 33 million lives nationwide. UnitedHealthcare affiliates include AmeriChoice, Great Lakes Health Plan, Health Net of CT, Oxford Health Plans, PacifiCare, Sierra Health and Life, among many others.  Excellus BCBS provides health insurance to approximately 1.6 million individuals across upstate New York.  

Uroplasty also announced that CIGNA Government Services, the new Medicare carrier for Kentucky effective May 1, 2011, will cover PTNS treatments effective that date.  This adds approximately 750,000 lives to the approximately 1.7 million CIGNA covers in Idaho and North Carolina. The addition of Kentucky extends PTNS coverage to approximately 30 million Medicare beneficiaries in 30 states.

"The expansion of PTNS coverage by these leading health insurance providers represents significant progress for our Company," said David Kaysen, President and CEO of Uroplasty, Inc. "We believe this expanded coverage reflects the strong clinical data that support the efficacy and safety of Urgent PC for the treatment of OAB and associated symptoms.  Along with key opinion leaders from the urology field, we continue to meet with other insurers to present the benefits of Urgent PC and anticipate that adoption and coverage of PTNS will continue to grow."

About Uroplasty, Inc.Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking InformationThis press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.For Further Information:Uroplasty, Inc. David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, Treasurer 952.426.6140 EVC Group Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820 Chris Gale (Media), 646.201.5431
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
3. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
4. Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009
5. Uroplasty Reports Results for Second Quarter FY2010
6. Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference
7. Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplastys Urgent® PC Neuromodulation System
8. Uroplasty to Present at The 5th Annual JMP Securities Healthcare Conference
9. Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010
10. Uroplasty Reports Financial Results for the Second Quarter FY2011
11. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... LONDON , Dec. 8, 2016 KEY ... for the largest share of the market in 2016 ... This dominance can be attributed to a large number ... region. (US hold the largest share in the patient ... several benefits such as reducing loss of blood during ...
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)...  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e ... doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, ... , , ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use ... nebulizer had a more child-friendly design, then children would be more likely to look ... to avoid the need to deliver medication via a nebulizer mask. The design will ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... NY (PRWEB) , ... December 08, 2016 , ... ... is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods ... in JMIR Medical Informatics . , Results of the comparative usability study ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
Breaking Medicine News(10 mins):